NASDAQ
NewcelX Ltd. - Ordinary Shares (NCEL)
♥ 420 Thanks from members
NewcelX Ltd. (NCEL) displays mixed market sentiment, driven by its strategic merger with Kadimastem, partnership with Eledon for Type 1 Diabetes therapy NCEL-101, and recent financing efforts, balanced against heavy historical net losses, going concern risks, and limited cash reserves.